Market Inference - Daily Stock Reports
WEBThe dividend has been raised to 79 cents per common share, representing a 10% increase from the previous quarter's dividend of 71.5 cents per share. Charles (Skip) Hageboeck, the president and CEO of City Holding Company, stated that the decision to increase the dividend to $3.16 on an annualized basis is based on the company's strong current ...
Zeta Global to Acquire LiveIntent for $250 Million
WEB15 hours ago · The transaction details reveal that Zeta will purchase LiveIntent for a total consideration of $250 million, consisting of $77.5 million in cash-on-hand and $172.5 million in common stock at closing. Furthermore, there is potential for an earnout of 50% cash and 50% stock tied to significant adjusted EBITDA growth and sustained margin expansion ...
Cassava Sciences CEO Updates Community on Clinical Trials and ...
WEB1 day ago · By Bobby Samwell • Tuesday, October 08 15:21 • Permanent Link. In an open letter to the Cassava community, President and CEO Rick Barry provided an update on the company's progress, particularly in its clinical trials and regulatory matters. The rethink phase 3 clinical trial, which enrolled 804 patients at 77 sites, has completed dosing ...
Market Inference: Today's Edition
WEBMerit Medical Acquires Cook Medical's Lead Management Portfolio. Market Inference combines deep investment knowledge, big data, and state of the art machine learning tools to create institutional quality stock reporting and investment analysis.
Moderna's R&D Progress & Strategic Priorities - Market Inference
WEBOct 2, 2024 · The company has implemented portfolio prioritization and cost efficiencies to reduce its R&D expense by $1.1 billion, from $4.8 billion in 2024 to $3.6-3.8 billion in 2027. Moderna's R&D strategy has shown significant success, with the combined probability of success across its mid* and late-stage pipeline at approximately 66%, compared to the ...
Graham: Your AI Equity Research Assistant
WEBUse AI to get the most recent financials from EDGAR and find unique investment opportunities. The equity research team at Market Inference joined forces with the industry leading AI innovators from Informatism, LLC to create a chatbot that can access, interpret, and report stock data. Just log in and start talking!
Unveiling the Momentum Driving Eli Lilly Stock.
WEB3 days ago · Here's a snapshot of some important facts to keep in mind about LLY: The stock has trailing 12 month earnings per share (EPS) of $8.16. Eli Lilly and has a trailing 12 month Price to Earnings (P/E) ratio of 117.6 compared to the S&P 500 average of 28.21. The company has a Price to Book (P/B) ratio of 63.74 in contrast to …
JPMorgan Chase & Stock in Brief - Market Inference
WEB4 days ago · Now trading at a price of $205.56, JPMorgan Chase & has moved -5.2% so far today. JPMorgan Chase & returned gains of 40.4% last year, with its stock price reaching a high of $225.48 and a low of $135.19. Over the same period, the stock outperformed the S&P 500 index by 17.4%. More recently, the company's 50-day average price was $211.03.
Graham
WEBSign in with email. Forgot your password?
Uncovering Insights – Analyzing BABA Stock - Market Inference
WEBSep 2, 2024 · Over the last 12 months BABA shares have declined by -11.9%, which represents a difference of -37.6% when compared to the S&P 500. The stock's 52 week high is $95.8 per share and its 52 week low is $66.63. With its net margins declining an average -15.3% over the last 6 years, Alibaba declining profitability gives us reason to believe its stock ...